JPWO2015137387A1 - Muscle enhancer - Google Patents
Muscle enhancer Download PDFInfo
- Publication number
- JPWO2015137387A1 JPWO2015137387A1 JP2016507786A JP2016507786A JPWO2015137387A1 JP WO2015137387 A1 JPWO2015137387 A1 JP WO2015137387A1 JP 2016507786 A JP2016507786 A JP 2016507786A JP 2016507786 A JP2016507786 A JP 2016507786A JP WO2015137387 A1 JPWO2015137387 A1 JP WO2015137387A1
- Authority
- JP
- Japan
- Prior art keywords
- salt
- amino acid
- weight
- citrulline
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003205 muscle Anatomy 0.000 title claims description 42
- 239000003623 enhancer Substances 0.000 title description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 101
- 239000000203 mixture Substances 0.000 claims abstract description 100
- 235000001014 amino acid Nutrition 0.000 claims abstract description 75
- 150000001413 amino acids Chemical class 0.000 claims abstract description 75
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract description 59
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 55
- 229960002173 citrulline Drugs 0.000 claims abstract description 54
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229960003104 ornithine Drugs 0.000 claims abstract description 51
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims abstract description 47
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 47
- 235000013477 citrulline Nutrition 0.000 claims abstract description 47
- 239000004475 Arginine Substances 0.000 claims abstract description 46
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 46
- 235000018102 proteins Nutrition 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 102000007544 Whey Proteins Human genes 0.000 claims description 20
- 108010046377 Whey Proteins Proteins 0.000 claims description 20
- 235000021119 whey protein Nutrition 0.000 claims description 20
- 238000005728 strengthening Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 235000002639 sodium chloride Nutrition 0.000 description 91
- 229940024606 amino acid Drugs 0.000 description 62
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 44
- 229960003121 arginine Drugs 0.000 description 41
- 235000009697 arginine Nutrition 0.000 description 41
- 235000013305 food Nutrition 0.000 description 23
- 238000000034 method Methods 0.000 description 20
- 235000013361 beverage Nutrition 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- -1 inorganic acid salts Chemical class 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000001243 protein synthesis Methods 0.000 description 12
- 230000014616 translation Effects 0.000 description 12
- 235000013373 food additive Nutrition 0.000 description 11
- 239000002778 food additive Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 102000008934 Muscle Proteins Human genes 0.000 description 10
- 108010074084 Muscle Proteins Proteins 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
- 229930064664 L-arginine Natural products 0.000 description 6
- 235000014852 L-arginine Nutrition 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000000748 compression moulding Methods 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000012262 fermentative production Methods 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- 239000004101 4-Hexylresorcinol Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- RHGKLRLOHDJJDR-SCSAIBSYSA-N D-citrulline Chemical compound OC(=O)[C@H](N)CCCNC(N)=O RHGKLRLOHDJJDR-SCSAIBSYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical class OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical class OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical class OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩からなるアミノ酸組成物を有効成分として含有する筋肉増強剤、ならびにオルニチンまたはその塩を10〜80重量%、シトルリンまたはその塩を10〜80重量%およびアルギニンまたはその塩を10〜80重量%からなるアミノ酸組成物ならびに該アミノ酸組成物に対して、1〜20倍の重量比の蛋白質を含有する組成物を提供する。Ornithine or a salt thereof, citrulline or a salt thereof and an amino acid composition comprising arginine or a salt thereof as an active ingredient, as well as ornithine or a salt thereof 10 to 80% by weight, citrulline or a salt thereof 10 to 80% by weight And a composition containing 10 to 80% by weight of arginine or a salt thereof, and a protein containing 1 to 20 times the weight ratio of the protein to the amino acid composition.
Description
本発明は、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物を有効成分として含有する筋肉増強剤に関する。また、本発明は、オルニチン、シトルリンおよびアルギニンまたはそれらの塩を含むアミノ酸組成物を有効成分として含有する組成物に関する。 The present invention relates to a muscle strengthening agent containing an amino acid composition containing ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof as an active ingredient. The present invention also relates to a composition comprising as an active ingredient an amino acid composition containing ornithine, citrulline and arginine or a salt thereof.
筋肉の維持および増強は、アスリートがより優れた運動パフォーマンスを発揮するために重要なだけでなく、一般健常者の日常生活にとっても重要である。具体的には、運動不足や老化によって筋肉が衰えると、立ったり座ったりといった日常動作にも支障をきたすことになる。そのため、運動負荷による筋力トレーニングや、筋肉増強効果を目的とした種々のサプリメントが用いられている。 Muscle maintenance and strengthening is not only important for athletes to achieve better athletic performance, but is also important for the normal life of a normal healthy individual. Specifically, when muscles weaken due to lack of exercise or aging, daily activities such as standing and sitting are also hindered. For this reason, various supplements are used for the purpose of muscular strength training by exercise load and muscle enhancement effect.
各種アミノ酸は、蛋白質の合成材料あるいは合成刺激として作用することで、筋蛋白質合成に寄与することが示されている (非特許文献1)。
オルニチン、シトルリンおよびアルギニンを含有する組成物としては、オルニチン、シトルリン、アルギニン等のアミノ酸および茶や茶の風味成分等を含むアミノ酸類食品組成物(特許文献1)、およびL-オルニチン塩酸塩、L-シトルリンおよびL-アルギニン塩酸塩を含有する外用クリーム組成物 (特許文献2) が報告されている。また、上記3種アミノ酸組成物を含有し、運動に伴って発生するアンモニア等の体外排出促進作用を謳うサプリメントとして「PheNOm (フェノム）」 (ボディプラスインターナショナル社製) が市販されている。Various amino acids have been shown to contribute to muscle protein synthesis by acting as a protein synthesis material or synthesis stimulus (Non-patent Document 1).
Compositions containing ornithine, citrulline and arginine include amino acids such as ornithine, citrulline and arginine, and amino acid food compositions containing tea and tea flavor components (Patent Document 1), and L-ornithine hydrochloride, L An external cream composition containing -citrulline and L-arginine hydrochloride (Patent Document 2) has been reported. In addition, “PheNOm” (manufactured by Body Plus International) is commercially available as a supplement containing the above-mentioned three amino acid compositions and enhancing the effect of promoting the elimination of ammonia and the like generated during exercise.
筋肉増強作用を有するアミノ酸含有組成物としては、例えばL-オルニチンを含有する筋肉増強剤(特許文献3) や、L-シトルリンによる筋蛋白質合成促進剤 (非特許文献2)、L-アルギニンによる筋蛋白質合成促進剤(非特許文献3) 等が報告されている。
しかし、オルニチン、シトルリンおよびアルギニンを含有する組成物を摂取することにより筋蛋白質合成が高まり筋肉量が増加することは知られていない。Examples of the amino acid-containing composition having a muscle-enhancing action include muscle-enhancing agents containing L-ornithine (Patent Document 3), muscle protein synthesis promoters using L-citrulline (Non-patent Document 2), muscles produced by L-arginine Protein synthesis accelerators (Non-patent Document 3) have been reported.
However, it is not known that ingestion of a composition containing ornithine, citrulline and arginine increases muscle protein synthesis and increases muscle mass.
本発明の目的は、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩からなるアミノ酸組成物を有効成分として含有する筋肉増強剤、ならびにオルニチンまたはその塩が10〜80重量%、シトルリンまたはその塩が10〜80重量%およびアルギニンまたはその塩が10〜80重量%からなるアミノ酸組成物ならびに該アミノ酸組成物に対して1〜20倍の重量比の蛋白質を含有する組成物を提供することにある。 An object of the present invention is to provide a muscle potentiator containing an amino acid composition comprising ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof as an active ingredient, and 10 to 80% by weight of ornithine or a salt thereof, citrulline or a salt thereof. To provide an amino acid composition comprising 10 to 80% by weight of a salt and 10 to 80% by weight of arginine or a salt thereof, and a composition containing a protein in a weight ratio of 1 to 20 times the amino acid composition. is there.
本発明は、下記の(1)〜(8)に関する。
(1) オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩からなるアミノ酸組成物を有効成分として含有する筋肉増強剤。
(2) 該アミノ酸組成物が、該アミノ酸組成物の全量に対して、オルニチンまたはその塩が10〜80重量%、シトルリンまたはその塩が10〜80重量%およびアルギニンまたはその塩が10〜80重量%からなるアミノ酸組成物である(1)記載の筋肉増強剤。
(3) アミノ酸としては、該アミノ酸組成物のみを含有する(1)または(2)記載の筋肉増強剤。
(4) (1)〜(3)のいずれかに記載の筋肉増強剤が、該アミノ酸組成物に対して1〜20倍の重量の蛋白質を含有する筋肉増強剤。
(5) 該蛋白質がホエイ蛋白質である(4)記載の筋肉増強剤。
(6) オルニチンまたはその塩を10〜80重量%、シトルリンまたはその塩を10〜80重量%およびアルギニンまたはその塩を10〜80重量%からなるアミノ酸組成物ならびに、該アミノ酸組成物に対して、1〜20倍の重量比の蛋白質を含有する組成物。
(7) 該蛋白質がホエイ蛋白質である(6)記載の組成物。
(8) アミノ酸としては、該アミノ酸組成物のみをその成分として含有する(6)または(7)記載の組成物。The present invention relates to the following (1) to (8).
(1) A muscle potentiator containing an amino acid composition comprising ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof as an active ingredient.
(2) The amino acid composition is 10 to 80% by weight of ornithine or a salt thereof, 10 to 80% by weight of citrulline or a salt thereof, and 10 to 80% by weight of arginine or a salt thereof based on the total amount of the amino acid composition. The muscle enhancer according to (1), which is an amino acid composition comprising%.
(3) The muscle enhancer according to (1) or (2), which contains only the amino acid composition as the amino acid.
(4) A muscle enhancer, wherein the muscle enhancer according to any one of (1) to (3) contains 1 to 20 times the weight of protein relative to the amino acid composition.
(5) The muscle enhancer according to (4), wherein the protein is a whey protein.
(6) An amino acid composition comprising 10-80% by weight of ornithine or a salt thereof, 10-80% by weight of citrulline or a salt thereof and 10-80% by weight of arginine or a salt thereof, and the amino acid composition, A composition containing a protein having a weight ratio of 1 to 20 times.
(7) The composition according to (6), wherein the protein is whey protein.
(8) The composition according to (6) or (7), wherein the amino acid contains only the amino acid composition as a component.
本発明により、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩からなるアミノ酸組成物を有効成分として含有する筋肉増強剤、ならびにオルニチンまたはその塩が10〜80重量%、シトルリンまたはその塩が10〜80重量%およびアルギニンまたはその塩が10〜80重量%からなるアミノ酸組成物ならびに該アミノ酸組成物に対して1〜20倍の重量比の蛋白質を含有する組成物を提供することができる。 According to the present invention, ornithine or a salt thereof, citrulline or a salt thereof and an amino acid composition consisting of arginine or a salt thereof as an active ingredient, a muscle enhancer, ornithine or a salt thereof is 10 to 80% by weight, citrulline or a salt thereof An amino acid composition comprising 10 to 80% by weight and 10 to 80% by weight of arginine or a salt thereof, and a composition containing a protein in a weight ratio of 1 to 20 times the amino acid composition can be provided.
本発明で用いられるオルニチン、シトルリンおよびアルギニンとしては、それぞれL体、D体、およびL体とD体の混合物のいずれを用いてもよいが、好ましくはL体を用いる。
オルニチンは、公知の方法である化学的に合成する方法、または発酵生産する方法等により取得することができる。また、オルニチンは、協和発酵バイオ株式会社等の各社の市販品を購入することにより入手することもできる。As ornithine, citrulline and arginine used in the present invention, any of L-form, D-form, and a mixture of L-form and D-form may be used, but L-form is preferably used.
Ornithine can be obtained by a known method such as chemical synthesis or fermentation. Ornithine can also be obtained by purchasing commercial products from various companies such as Kyowa Hakko Bio Co., Ltd.
オルニチンを化学的に合成する方法としては、例えばColl.Czechoslov.Chem.Commun,24,1993 (1959) に記載の方法等が挙げられる。
オルニチンを発酵生産する方法としては、例えば、特開昭53-24096号、特開昭61-119194等に記載の方法があげられる。
また、L-オルニチンおよびD-オルニチンは、シグマ−アルドリッチ社等より購入することもできる。Examples of the method for chemically synthesizing ornithine include the method described in Coll.Czechoslov.Chem.Commun, 24, 1993 (1959).
Examples of the method for fermentative production of ornithine include the methods described in JP-A Nos. 53-24096 and 61-119194.
L-ornithine and D-ornithine can also be purchased from Sigma-Aldrich.
シトルリンは、公知の方法である化学的に合成する方法、または発酵生産する方法等により取得することができる。また、シトルリンは、協和発酵バイオ株式会社等の各社の市販品を購入することにより入手することもできる。
シトルリンを化学的に合成する方法としては、例えば、J. Biol. Chem. 122, 477 (1938)、J. Org. Chem. 6, 410 (1941) に記載の方法があげられる。Citrulline can be obtained by a known method of chemically synthesizing or fermentative production. Citrulline can also be obtained by purchasing commercial products from various companies such as Kyowa Hakko Bio Co., Ltd.
Examples of methods for chemically synthesizing citrulline include the methods described in J. Biol. Chem. 122, 477 (1938) and J. Org. Chem. 6, 410 (1941).
L-シトルリンを発酵生産する方法としては、例えば、特開昭53-075387、特開昭63-068091に記載の方法があげられる。
また、L-シトルリンおよびD-シトルリンは、シグマ−アルドリッチ社等より購入することもできる。
アルギニンは、公知の方法である化学的に合成する方法、または発酵生産する方法等により取得することができる。また、アルギニンは、協和発酵バイオ株式会社等の各社の市販品を購入することにより入手することもできる。Examples of the method for producing L-citrulline by fermentation include the methods described in JP-A-53-075387 and JP-A-63-068091.
L-citrulline and D-citrulline can also be purchased from Sigma-Aldrich.
Arginine can be obtained by a known method such as chemical synthesis or fermentation production. Arginine can also be obtained by purchasing commercial products from various companies such as Kyowa Hakko Bio Co., Ltd.
L-アルギニンを発酵生産する方法としては、例えば、特開平6-000092、Agricultural & Biological Chemistry, 36, 1675 (1972) に記載の方法があげられる。
また、L-アルギニンおよびD-アルギニンは、シグマ−アルドリッチ社等より購入することもできる。
オルニチン、シトルリンおよびアルギニンの塩としては、それぞれ、同一または異なって、例えば、酸付加塩、金属塩、アンモニウム塩、有機アミン付加塩、アミノ酸付加塩等が挙げられる。Examples of the method for fermentative production of L-arginine include the methods described in JP-A-6-000092, Agricultural & Biological Chemistry, 36, 1675 (1972).
L-arginine and D-arginine can also be purchased from Sigma-Aldrich.
The salts of ornithine, citrulline and arginine are the same or different and include, for example, acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
酸付加塩としては、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩、酢酸塩、マレイン酸塩、フマル酸塩、クエン酸塩、リンゴ酸塩、乳酸塩、α-ケトグルタル酸塩、グルコン酸塩、カプリル酸塩等の有機酸塩が挙げられる。
金属塩としては、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩、マグネシウム塩、カルシウム塩等のアルカリ土類金属塩、アルミニウム塩、亜鉛塩等が挙げられる。Examples of acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate, acetate, maleate, fumarate, citrate, malate, lactate, α-ketoglutar Organic acid salts such as acid salts, gluconates and caprylates can be mentioned.
Examples of the metal salt include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, zinc salt and the like.
アンモニウム塩としては、例えば、アンモニウム、テトラメチルアンモニウムの塩等が挙げられる。
有機アミン付加塩としては、例えば、モルホリン、ピペリジンの塩等が挙げられる。
アミノ酸付加塩としては、例えば、グリシン、フェニルアラニン、リジン、アスパラギン酸、グルタミン酸の塩等が挙げられる。Examples of ammonium salts include ammonium and tetramethylammonium salts.
Examples of organic amine addition salts include morpholine and piperidine salts.
Examples of amino acid addition salts include salts of glycine, phenylalanine, lysine, aspartic acid, glutamic acid, and the like.
本発明における「アミノ酸組成物」とは、本発明の組成物全体のうち、蛋白質以外の部分のオルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩からなる混合物を表す。
アミノ酸組成物は、本発明の組成物全体の重量に対して0.1〜99重量%、好ましくは1〜10重量%、さらに好ましくは2〜5重量%である。The “amino acid composition” in the present invention represents a mixture comprising ornithine or a salt thereof, citrulline or a salt thereof, and arginine or a salt thereof other than the protein in the entire composition of the present invention.
The amino acid composition is 0.1 to 99% by weight, preferably 1 to 10% by weight, more preferably 2 to 5% by weight, based on the total weight of the composition of the present invention.
アミノ酸組成物に対する各アミノ酸の重量％としては、オルニチンまたはその塩が10〜80重量%、シトルリンまたはその塩が10〜80重量%およびアルギニンまたはその塩が10〜80重量％であり、オルニチンまたはその塩が25〜50重量%、シトルリンまたはその塩が25〜50重量%およびアルギニンまたはその塩が25〜50重量%であるのが好ましい。
本発明におけるオルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩の比率としては、オルニチンまたはその塩：シトルリンまたはその塩：アルギニンまたはその塩＝8：1：1〜1：8：1または1：8：1〜1：1：8が好ましく、オルニチンまたはその塩：シトルリンまたはその塩：アルギニンまたはその塩＝1：1：1〜1：1：2がより好ましい。The weight percent of each amino acid with respect to the amino acid composition is ornithine or a salt thereof from 10 to 80% by weight, citrulline or a salt thereof from 10 to 80% by weight, and arginine or a salt thereof from 10 to 80% by weight. Preferably, the salt is 25-50% by weight, citrulline or a salt thereof is 25-50% by weight and arginine or a salt thereof is 25-50% by weight.
As the ratio of ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof in the present invention, ornithine or a salt thereof: citrulline or a salt thereof: arginine or a salt thereof = 8: 1: 1 to 1: 8: 1 or 1 : 8: 1 to 1: 1: 8 is preferable, ornithine or a salt thereof: citrulline or a salt thereof: arginine or a salt thereof = 1: 1: 1 to 1: 1: 2 is more preferable.
本発明における「蛋白質」としては、例えばカゼイン蛋白質、大豆蛋白質、卵蛋白質、小麦蛋白質、ホエイ蛋白質等が挙げられ、ホエイ蛋白質が好ましい。
本発明における「蛋白質」は、組成物全体の重量に対して、1〜99重量%であり、5〜95重量%が好ましく、10〜90重量%がより好ましい。
本発明の組成物は、医薬または食品添加剤（以下、本発明の医薬または食品添加剤ともいう）として用いることができる。Examples of the “protein” in the present invention include casein protein, soybean protein, egg protein, wheat protein, whey protein and the like, and whey protein is preferable.
The “protein” in the present invention is 1 to 99% by weight, preferably 5 to 95% by weight, more preferably 10 to 90% by weight, based on the weight of the entire composition.
The composition of the present invention can be used as a pharmaceutical or food additive (hereinafter also referred to as the pharmaceutical or food additive of the present invention).
本発明の組成物を医薬として用いる場合、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物をそのまま投与することも可能であるが、通常各種の製剤として提供するのが望ましい。
製剤は、有効成分としてオルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物を含有するが、更に任意の他の治療のための有効成分を含有していてもよい。また、それら医薬製剤は、有効成分を薬理学的に許容される一種またはそれ以上の担体と一緒に混合し、製剤学の技術分野においてよく知られている任意の方法により製造される。When the composition of the present invention is used as a medicament, an amino acid composition containing ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof can be administered as it is, but is usually provided as various preparations. desirable.
The preparation contains an amino acid composition containing ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof as active ingredients, but may further contain any other active ingredient for treatment. These pharmaceutical preparations are produced by any method well known in the technical field of pharmaceutics by mixing the active ingredient with one or more pharmacologically acceptable carriers.
製剤の投与形態は、治療に際し最も効果的なものを使用するのが望ましく、経口投与または、例えば静脈内、腹膜内もしくは皮下投与等の非経口投与をあげることができるが、経口投与が好ましい。
投与する剤形としては、例えば錠剤、散剤、顆粒剤、丸剤、懸濁剤、乳剤、浸剤・煎剤、カプセル剤、シロップ剤、液剤、エリキシル剤、エキス剤、チンキ剤、流エキス剤等の経口剤、注射剤、点滴剤、クリーム剤、坐剤等の非経口剤のいずれでもよいが、経口剤として好適に用いられる。As the dosage form of the preparation, it is desirable to use the most effective form in treatment, and oral administration or parenteral administration such as intravenous, intraperitoneal or subcutaneous administration can be mentioned, but oral administration is preferred.
Examples of dosage forms to be administered include tablets, powders, granules, pills, suspensions, emulsions, soaking and decoction, capsules, syrups, solutions, elixirs, extracts, tinctures, fluid extracts, etc. Any of parenteral preparations such as oral preparations, injection preparations, instillation preparations, cream preparations, and suppositories may be used, but they are preferably used as oral preparations.
経口投与に適当な、例えばシロップ剤のような液体調製物は、水、蔗糖、ソルビトール、果糖等の糖類、ポリエチレングリコール、プロピレングリコール等のグリコール類、ごま油、オリーブ油、大豆油等の油類、p-ヒドロキシ安息香酸エステル類等の防腐剤、パラオキシ安息香酸メチル等のパラオキシ安息香酸誘導体、安息香酸ナトリウム等の保存剤、ストロベリーフレーバー、ペパーミント等のフレーバー類などを添加して製剤化することができる。 Liquid preparations, such as syrups, suitable for oral administration include saccharides such as water, sucrose, sorbitol, fructose, glycols such as polyethylene glycol, propylene glycol, oils such as sesame oil, olive oil, soybean oil, p -Preservatives such as -hydroxybenzoic acid esters, paraoxybenzoic acid derivatives such as methyl paraoxybenzoate, preservatives such as sodium benzoate, and flavors such as strawberry flavor and peppermint can be added to prepare a preparation.
また、経口投与に適当な、例えば錠剤、散剤および顆粒剤等は、乳糖、白糖、ブドウ糖、蔗糖、マンニトール、ソルビトール等の糖類、バレイショ、コムギ、トウモロコシ等の澱粉、炭酸カルシウム、硫酸カルシウム、炭酸水素ナトリウム、塩化ナトリウム等の無機物、結晶セルロース、カンゾウ末、ゲンチアナ末等の植物末等の賦形剤、澱粉、寒天、ゼラチン末、結晶セルロース、カルメロースナトリウム、カルメロースカルシウム、炭酸カルシウム、炭酸水素ナトリウム、アルギン酸ナトリウム等の崩壊剤、ステアリン酸マグネシウム、タルク、水素添加植物油、マクロゴール、シリコーン油等の滑沢剤、ポリビニールアルコール、ヒドロキシプロピルセルロース、メチルセルロース、エチルセルロース、カルメロース、ゼラチン、澱粉のり液等の結合剤、脂肪酸エステル等の界面活性剤、グリセリン等の可塑剤などを添加して製剤化することができる。 Also suitable for oral administration, such as tablets, powders and granules are lactose, sucrose, glucose, sucrose, mannitol, sorbitol and other sugars, potato, wheat, corn and other starches, calcium carbonate, calcium sulfate, hydrogen carbonate Inorganic substances such as sodium and sodium chloride, excipients such as crystalline cellulose, licorice powder and gentian powder, etc., starch, agar, gelatin powder, crystalline cellulose, carmellose sodium, carmellose calcium, calcium carbonate, sodium bicarbonate , Disintegrants such as sodium alginate, magnesium stearate, talc, hydrogenated vegetable oil, macrogol, silicone oil and other lubricants, polyvinyl alcohol, hydroxypropylcellulose, methylcellulose, ethylcellulose, carmellose, gelatin, starch Ri binders such as liquid, surfactants such as fatty acid esters can be formulated by adding a plasticizer such as glycerin.
非経口投与に適当な、例えば注射剤は、好ましくは受容者の血液と等張であるオルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物を含む滅菌水性剤からなる。例えば、注射剤の場合は、塩溶液、ブドウ糖溶液または塩溶液とブドウ糖溶液の混合物からなる担体等を用いて注射用の溶液を調製する。また、これら非経口剤においても、経口剤で例示した防腐剤、保存剤、フレーバー類、賦形剤、崩壊剤、滑沢剤、結合剤、界面活性剤、可塑剤などから選択される1種またはそれ以上の補助成分を添加することができる。 Suitable for parenteral administration, for example injections, consist of sterile aqueous preparations comprising an amino acid composition comprising ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof, preferably isotonic with the blood of the recipient. For example, in the case of an injection, a solution for injection is prepared using a carrier such as a salt solution, a glucose solution, or a mixture of a salt solution and a glucose solution. In these parenterals, one kind selected from antiseptics, preservatives, flavors, excipients, disintegrants, lubricants, binders, surfactants, plasticizers and the like exemplified in the oral preparations. Or more auxiliary components can be added.
本発明の医薬中のオルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物の濃度は、製剤の種類、当該製剤の投与により期待する効果等に応じて適宜選択されるが、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物として、通常は0.1〜100重量％、好ましくは0.5〜80重量％、特に好ましくは1〜70重量％である。 The concentration of the amino acid composition containing ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof in the medicament of the present invention is appropriately selected according to the type of preparation, the effect expected by administration of the preparation, and the like. The amino acid composition containing ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof is usually 0.1 to 100% by weight, preferably 0.5 to 80% by weight, particularly preferably 1 to 70% by weight.
本発明の医薬の投与量および投与回数は、投与形態、患者の年齢、体重、治療すべき症状の性質もしくは重篤度により異なるが、通常、成人一日当り、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩からなるアミノ酸組成物として、通常は100 mg〜5 g、好ましくは150 mg〜4 g、さらに好ましくは200 mg〜3 gとなるように1日1回ないし数回投与する。 The dose and frequency of administration of the medicament of the present invention vary depending on the administration form, patient age, body weight, nature or severity of the symptoms to be treated, and are usually per day for adults ornithine or a salt thereof, citrulline or a salt thereof. As an amino acid composition comprising arginine or a salt thereof, it is usually administered once to several times a day so as to be 100 mg to 5 g, preferably 150 mg to 4 g, more preferably 200 mg to 3 g.
投与期間は、特に限定されないが、通常は1日間〜1年間、好ましくは1週間〜3ヶ月間である。
本発明の組成物を食品添加剤として用いる場合、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物をそのまま使用することも可能であるが、上記の製剤と同様な方法により、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物を有効成分として含有する食品添加剤を調製してもよい。The administration period is not particularly limited, but is usually 1 day to 1 year, preferably 1 week to 3 months.
When the composition of the present invention is used as a food additive, ornithine or a salt thereof, citrulline or a salt thereof and an amino acid composition containing arginine or a salt thereof can be used as they are, but the same method as the above preparation According to the present invention, a food additive containing an amino acid composition containing ornithine or a salt thereof, citrulline or a salt thereof and arginine or a salt thereof as an active ingredient may be prepared.
本発明の食品添加剤は、必要に応じて他の食品添加剤を混合または溶解し、例えば粉末、顆粒、ペレット、錠剤、各種液剤の形態に加工、製造される。
本発明の食品添加剤を含有する飲食品（以下、本発明の飲食品ともいう）は、飲食品中に本発明の食品添加剤を添加する以外は、一般的な飲食品の製造方法を用いることにより、加工、製造することができる。The food additive of the present invention is processed or manufactured by mixing or dissolving other food additives as required, for example, in the form of powder, granules, pellets, tablets, or various liquids.
The food / beverage products containing the food additive of the present invention (hereinafter also referred to as the food / beverage product of the present invention) use a general method for producing a food / beverage product, except that the food additive of the present invention is added to the food / beverage product. Thus, it can be processed and manufactured.
また、本発明の飲食品は、例えば流動層造粒、攪拌造粒、押し出し造粒、転動造粒、気流造粒、圧縮成形造粒、解砕造粒、噴霧造粒、噴射造粒等の造粒方法、パンコーティング、流動層コーティング、ドライコーティング等のコーティング方法、パフドライ、過剰水蒸気法、フォームマット方法、マイクロ波加熱方法等の膨化方法、押出造粒機やエキストルーダー等の押出方法等を用いて製造することもできる。 The food and drink of the present invention are, for example, fluidized bed granulation, stirring granulation, extrusion granulation, rolling granulation, airflow granulation, compression molding granulation, pulverization granulation, spray granulation, spray granulation, etc. Granulation method, coating method such as pan coating, fluidized bed coating, dry coating, puff drying, excess steam method, foam mat method, expansion method such as microwave heating method, extrusion method such as extrusion granulator and extruder etc. It can also be manufactured using.
本発明の飲食品としては、例えばジュース類、清涼飲料水、茶類、乳酸菌飲料、発酵乳、冷菓、バター、チーズ、ヨーグルト、加工乳、脱脂乳等の乳製品、ハム、ソーセージ、ハンバーグ等の畜肉製品、蒲鉾、竹輪、さつま揚げ等の魚肉練り製品、だし巻き、卵豆腐等の卵製品、クッキー、ゼリー、チューインガム、キャンディー、スナック菓子等の菓子類、パン類、麺類、漬物類、燻製品、干物、佃煮、塩蔵品、スープ類、調味料等、いずれの形態のものであってもよい。 Examples of the food and drink of the present invention include juices, soft drinks, teas, lactic acid bacteria beverages, fermented milk, frozen desserts, butter, cheese, yogurt, processed milk, skim milk and other dairy products, ham, sausage, hamburger and the like. Livestock meat products, fish paste products such as bamboo shoots, bamboo rings and fried fish, egg products such as broiled and egg tofu, cookies, jelly, chewing gum, candy, snacks and other confectionery, breads, noodles, pickles, salmon products, dried fish, It may be in any form such as boiled salmon, salted products, soups, seasonings and the like.
また、本発明の飲食品は、例えば粉末食品、シート状食品、瓶詰め食品、缶詰食品、レトルト食品、カプセル食品、タブレット状食品、流動食品、ドリンク剤等の形態のものであってもよい。
本発明の飲食品は、筋肉を増強させるための健康食品、機能性食品、栄養補助食品、特定保健用食品等の飲食品として用いることができる。The food and drink of the present invention may be in the form of, for example, powdered food, sheet food, bottled food, canned food, retort food, capsule food, tablet food, liquid food, and drink.
The food / beverage products of the present invention can be used as food / beverage products such as health foods, functional foods, dietary supplements, foods for specified health use, etc. for strengthening muscles.
本発明の食品添加剤または飲食品には、一般に飲食品に用いられる添加剤、例えば食品添加物表示ハンドブック（日本食品添加物協会、平成9年1月6日発行）に記載されている甘味料、着色料、保存料、増粘安定剤、酸化防止剤、発色剤、漂白剤、防かび剤、ガムベース、苦味料、酵素、光沢剤、酸味料、調味料、乳化剤、強化剤、製造用剤、香料、香辛料抽出物等が添加されてもよい。 The food additive or food / beverage product of the present invention includes additives generally used in food / beverage products, for example, sweeteners described in the Food Additives Display Handbook (Japan Food Additives Association, issued on January 6, 1997) , Coloring agent, Preservative, Thickening stabilizer, Antioxidant, Coloring agent, Bleaching agent, Antifungal agent, Gum base, Bittering agent, Enzyme, Brightener, Acidulant, Seasoning, Emulsifier, Strengthening agent, Production agent A fragrance, a spice extract, etc. may be added.
本発明の飲食品中への本発明の食品添加剤の添加量は、飲食品の種類、当該飲食品の摂取により期待する効果等に応じて適宜選択されるが、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物として、通常は0.1〜90重量％、好ましくは0.5〜80重量％、特に好ましくは1〜70重量％含有するように添加される。 The amount of the food additive of the present invention added to the food or drink of the present invention is appropriately selected according to the type of food or drink, the effect expected from the intake of the food or drink, ornithine or a salt thereof, citrulline or The salt and arginine or an amino acid composition containing the salt are usually added so as to contain 0.1 to 90% by weight, preferably 0.5 to 80% by weight, particularly preferably 1 to 70% by weight.
本発明の飲食品の摂取量は、摂取形態、摂取者の年齢、体重等に応じて異なるが、通常成人一日あたり、オルニチンまたはその塩、シトルリンまたはその塩およびアルギニンまたはその塩を含むアミノ酸組成物として、100 mg〜5 g、好ましくは150 mg〜4 g、さらに好ましくは200 mg〜3 gとなるように1日1回ないし数回摂取する。
摂取期間は特に限定はないが、通常は1日間〜1年間、好ましくは1日間〜3ヶ月間、さらに好ましくは1日間〜1ヶ月間である。The intake of the food and drink according to the present invention varies depending on the intake form, the age of the user, the body weight, etc., but usually an ornithine or a salt thereof, citrulline or a salt thereof and an amino acid composition containing arginine or a salt thereof per adult day As a product, it is taken once to several times a day so as to be 100 mg to 5 g, preferably 150 mg to 4 g, more preferably 200 mg to 3 g.
The intake period is not particularly limited, but is usually 1 day to 1 year, preferably 1 day to 3 months, and more preferably 1 day to 1 month.
本発明の筋肉増強作用は、筋肉量増加作用およびそれに伴う筋力の増加作用を意味する。
筋肉量の増加は、筋繊維の増加、結合組織の増加、間質液の増加の3つに大別され、筋力増加を伴う筋肉量増加の主要な部分は筋繊維の増加であることが知られている。また、筋繊維の増加は筋蛋白質合成速度の増加、分解速度の減少、あるいはその両作用によるものと考えられている。(「運動と筋の科学」、2000年、p84〜85)
以下に、筋肉増強剤の筋蛋白質合成促進作用および筋湿重量増加作用を調べた試験例を示す。
試験例1．筋蛋白質合成促進作用
L-オルニチン、L-シトルリンおよびL-アルギニンが1:1:1の重量比からなるアミノ酸組成物を使用し、下記表1に示す組成比で基礎飼料 (Cont.)、10重量％ホエイ蛋白質 (WP10)、10重量%ホエイ蛋白質および5重量%アミノ酸組成物 (WP10+AA5) ならびに5重量%アミノ酸組成物 (AA5) の各飼料を作成した。The muscle strengthening action of the present invention means an action for increasing muscle mass and an accompanying action for increasing muscle strength.
The increase in muscle mass can be broadly divided into three categories: increase in muscle fiber, increase in connective tissue, and increase in interstitial fluid, and it is known that the main part of the increase in muscle mass accompanying the increase in muscle strength is the increase in muscle fiber. It has been. The increase in muscle fiber is thought to be due to an increase in muscle protein synthesis rate, a decrease in degradation rate, or both. ("Science of exercise and muscle", 2000, p84-85)
The following is a test example in which the muscle protein synthesis promoting action and the muscle wet weight increasing action of the muscle enhancer were examined.
Test Example 1. Muscle protein synthesis promoting effect
Using an amino acid composition having a 1: 1: 1 weight ratio of L-ornithine, L-citrulline and L-arginine, the basic feed (Cont.), 10% whey protein ( WP10), 10 wt% whey protein and 5 wt% amino acid composition (WP10 + AA5) and 5 wt% amino acid composition (AA5) were prepared.
試験群は、各飼料に対応する基礎飼料群(Cont.）、10重量％ホエイ蛋白質群 (WP10)、10重量%ホエイ蛋白質および5重量%アミノ酸組成物群 (WP10+AA5) ならびに5重量%アミノ酸組成物群(AA5) の計4群を設けた。 The test groups were the basic feed group (Cont.), 10 wt% whey protein group (WP10), 10 wt% whey protein and 5 wt% amino acid composition group (WP10 + AA5) and 5 wt% amino acids corresponding to each feed A total of 4 groups of composition groups (AA5) were provided.
被験動物として、一群につき6匹のSD系雄ラット (5週齢、日本SLC社製) を1週間予備飼育して馴化させ、予備飼育期間中は自由摂取 (CE-2固形飼料) 及び自由飲水とした。馴化後、表1中の基礎飼料 (Cont.) を用いてラットに給餌トレーニングを4日間実施した。試験前日から絶食させて、試験当日に筋蛋白質合成トレーサーとして重水 (0.9% NaCl含有)を腹腔内投与し、各試験飼料を個体当たり4 g摂取させた。重水トレーサー法によって投与後5時間までの筋蛋白質合成速度を測定した結果を図１に示す。本発明の筋肉増強剤、または組成物であるWP10+AA5群およびAA5群では、Cont.群と比較して有意に筋蛋白質合成速度が向上することが分かった。
試験例2．筋湿重量増加作用
L-オルニチン、L-シトルリンおよびL-アルギニンが1:1:1の重量比からなるアミノ酸組成物を使用し、下記表2に示す組成比で基礎飼料 (Cont.)、10重量％ホエイ蛋白質 (WP10)ならびに10重量%ホエイ蛋白質および5重量%アミノ酸組成物 (WP10+AA2) の各飼料を作成した。As test animals, 6 SD male rats (5-week-old, manufactured by Japan SLC) per group were preliminarily bred for 1 week, allowed to habituate during the pre-breeding period, CE-2 solid feed, and free drinking water It was. After habituation, the rats were subjected to feeding training for 4 days using the basic diet (Cont.) In Table 1. Fasted from the day before the test, heavy water (containing 0.9% NaCl) was intraperitoneally administered as a muscle protein synthesis tracer on the test day, and 4 g of each test feed was ingested per individual. The results of measuring the muscle protein synthesis rate up to 5 hours after administration by the heavy water tracer method are shown in FIG. It was found that the muscle protein synthesis rate was significantly improved in the WP10 + AA5 group and AA5 group, which are the muscle potentiators or compositions of the present invention, as compared to the Cont. Group.
Test Example 2. Muscle wet weight increase action
Using an amino acid composition having a 1: 1: 1 weight ratio of L-ornithine, L-citrulline and L-arginine, the basic feed (Cont.), 10% whey protein ( WP10) and 10 wt% whey protein and 5 wt% amino acid composition (WP10 + AA2) were prepared.
試験群は、各飼料に対応する基礎飼料群(Cont.)、10重量%ホエイ蛋白質群 (WP10)ならびに10重量%ホエイ蛋白質および2重量%アミノ酸組成物群 (WP10+AA2) の計3群を設けた。 The test group consists of three groups: a basic feed group (Cont.) Corresponding to each feed, a 10 wt% whey protein group (WP10), and a 10 wt% whey protein and 2 wt% amino acid composition group (WP10 + AA2). Provided.
被験動物として、一群につき3匹のSD系雄ラット (5週齢、日本SLC社製) を用いて予備飼育後、ラットを上記3群に分け、表2に示す試験飼料を自由摂取させ21日間飼育した。試験期間中のラットの試験試料の1日摂取量は、平均20.6 g〜22.9 g／匹であり、試験群による有意差は認められなかった。試験終了日に、ラットを屠殺し左右両後肢下腿の足底筋および腓腹筋を速やかに摘出し、生理食塩水で筋を洗浄後、余分な結合組織や脂肪等を除去し、筋湿重量を測定して、体重当たりの筋湿重量を求めた結果を図2に示す。本発明の筋肉増強剤または組成物であるWP10+AA2群では、Cont.群およびWP10群と比較して筋湿重量が増加し、筋肉増強作用を示すことが分かった。 As test animals, 3 SD male rats (5 weeks old, manufactured by Japan SLC) per group were preliminarily raised, and the rats were divided into the above 3 groups, and the test feed shown in Table 2 was allowed to be freely ingested for 21 days. Raised. The daily intake of rat test samples during the test period averaged 20.6 g to 22.9 g / animal, and no significant difference was observed between the test groups. At the end of the test, the rats were sacrificed, the plantar muscles and gastrocnemius muscles of both left and right hind limbs were quickly removed, the muscles were washed with physiological saline, excess connective tissue and fat were removed, and the muscle wet weight was measured. FIG. 2 shows the result of determining the muscle wet weight per body weight. In the WP10 + AA2 group, which is the muscle potentiator or composition of the present invention, it was found that the muscle wet weight increased compared to the Cont. Group and the WP10 group, and showed a muscle strengthening action.
WP10+AA5組成物
L-オルニチン塩酸塩 (協和発酵バイオ社)、L-シトルリン (協和発酵バイオ社製)、L-アルギニン (協和発酵バイオ社製) をそれぞれ1.28：1：1の重量比で量りとり、均一に混合してオルニチン：シトルリン：アルギニン＝1：1：1のアミノ酸組成物を作成した。該アミノ酸組成物、ホエイ蛋白質 (日本新薬社) および各飼料原料 (いずれも日本クレア社製) を表１中の「WP10+AA5」の組成に従って測りとり、乳鉢および撹拌ミキサーを使用して均一に混合し、試験飼料を得た。WP10 + AA5 composition
L-ornithine hydrochloride (Kyowa Hakko Bio), L-citrulline (Kyowa Hakko Bio), and L-arginine (Kyowa Hakko Bio) were weighed in a weight ratio of 1.28: 1: 1 and mixed uniformly. Then, an amino acid composition of ornithine: citrulline: arginine = 1: 1: 1 was prepared. Measure the amino acid composition, whey protein (Nippon Shinyaku Co., Ltd.) and each feed ingredient (all manufactured by Nippon Claire Co., Ltd.) according to the composition of “WP10 + AA5” in Table 1, and use a mortar and a stirring mixer to uniformly Mix to obtain a test feed.
WP10+AA2組成物
実施例1のアミノ酸組成物とホエイ蛋白質 (日本新薬社) および各飼料原料 (日本クレア社) を表2中の「WP10+AA2」の組成に従って量りとり、乳鉢および撹拌ミキサーを使用して均一に混合し、試験飼料を得た。WP10 + AA2 Composition Weigh the amino acid composition of Example 1 and whey protein (Nippon Shinyaku Co., Ltd.) and each feed ingredient (Nippon Claire Co., Ltd.) according to the composition of WP10 + AA2 in Table 2. Used to mix uniformly to obtain a test feed.
オルニチン、シトルリンおよびアルギニンを含有する錠剤の製造
実施例1で作成したアミノ酸組成物136.2 kg、微結晶セルロース36.0 kg（旭化成ケミカルズ社製、アビセルFD101）、ショ糖脂肪酸エステル6.6 kg（第一工業製薬社製、DKエステルF-20W）、リン酸カルシウム1.2 kg (太平化学産業社製、リン酸三カルシウム) およびβ-シクロデキストリン20.0 kg (日本食品化工社製、セルデックスB-100) を、コニカルブレンダー（日本乾燥機株式会社製、CB-1200ブレンダー）を用いて混合する。得られた混合物をロータリー圧縮成形機（菊水制作所社製、VIRGO524SS1AY）を用いて、圧縮成形圧10 kNで圧縮成形し、直径8 mm、250 mgの錠剤を製造する。Manufacture of tablets containing ornithine, citrulline and arginine 136.2 kg of amino acid composition prepared in Example 1, 36.0 kg of microcrystalline cellulose (Asahi Kasei Chemicals, Avicel FD101), 6.6 kg of sucrose fatty acid ester (Daiichi Kogyo Seiyaku Co., Ltd.) DK ester F-20W), calcium phosphate 1.2 kg (Taihei Chemical Industry Co., Ltd., tricalcium phosphate) and β-cyclodextrin 20.0 kg (Nihon Shokuhin Kako Co., Ltd., Celdex B-100), Conical Blender (Japan) Mix using a dryer (CB-1200 blender). The obtained mixture is compression-molded at a compression molding pressure of 10 kN using a rotary compression molding machine (VIRGO524SS1AY, manufactured by Kikusui Seisakusho Co., Ltd.) to produce tablets with a diameter of 8 mm and 250 mg.
オルニチン、シトルリンおよびアルギニンを含有する錠剤の製造
実施例1で作成したアミノ酸組成物120 kg、環状オリゴ糖19 kg、セルロース57 kgおよびプルラン1 kgを流動層造粒乾燥機で造粒する。得られる造粒物とステアリン酸カルシウム3 kgとをコニカルブレンダーで混合した後、ロータリー圧縮成形機で圧縮成形して錠剤を製造する。Production of tablets containing ornithine, citrulline and arginine 120 kg of the amino acid composition prepared in Example 1, 19 kg of cyclic oligosaccharide, 57 kg of cellulose and 1 kg of pullulan are granulated in a fluidized bed granulator / dryer. The obtained granulated product and 3 kg of calcium stearate are mixed with a conical blender, and then compressed with a rotary compression molding machine to produce a tablet.
オルニチン、シトルリンおよびアルギニンを含有する腸溶カプセルの製造
実施例1で作成したアミノ酸組成物120 kg、環状オリゴ糖19 kg、セルロース57 kg、ステアリン酸カルシウム3 kgおよびプルラン1 kgを、コニカルブレンダーで混合する。得られる混合物20 kgと0.2 kgの二酸化ケイ素とを混合攪拌して得られる混合物をカプセル充填機に投入、ハードカプセルに充填してハードカプセルを得る。得られるハードカプセルの表面をツェイン溶液でコーティングして腸溶カプセルを製造する。Production of enteric capsule containing ornithine, citrulline and arginine 120 kg of amino acid composition prepared in Example 1, 19 kg of cyclic oligosaccharide, 57 kg of cellulose, 3 kg of calcium stearate and 1 kg of pullulan are mixed in a conical blender. . A mixture obtained by mixing and stirring 20 kg of the obtained mixture and 0.2 kg of silicon dioxide is put into a capsule filling machine and filled into hard capsules to obtain hard capsules. The surface of the resulting hard capsule is coated with a zein solution to produce an enteric capsule.
オルニチン、シトルリンおよびアルギニンを含有する顆粒の製造
実施例1で作成したアミノ酸組成物450 g、リン酸カルシウム(第三リン酸カルシウム) 7.5 gおよびマルチトール) 1035 gを混合し、流動層造粒機を用いて5%プルラン水溶液150 gを噴霧して造粒し、顆粒を得る。Production of granules containing ornithine, citrulline and arginine 450 g of the amino acid composition prepared in Example 1, 7.5 g of calcium phosphate (tricalcium phosphate) and 1035 g of maltitol were mixed and mixed using a fluid bed granulator. Granulate by spraying 150 g of aqueous solution of% pullulan.
オルニチン、シトルリンおよびアルギニンを含有する飲料の製造(1)
実施例1で作成したアミノ酸組成物1.28 kg、エリスリトール3 kg、クエン酸0.05 kg、人工甘味料3 g、香料0.06 kgを液温70 ℃で水50 Lに攪拌溶解し、クエン酸でpHを3.3に調整後、プレート殺菌を用いて滅菌して瓶に充填後、パストライザー殺菌し、飲料を製造する。Manufacture of beverages containing ornithine, citrulline and arginine (1)
1.28 kg of the amino acid composition prepared in Example 1, 3 kg of erythritol, 0.05 kg of citric acid, 3 g of artificial sweetener, 0.06 kg of fragrance were stirred and dissolved in 50 L of water at a liquid temperature of 70 ° C., and the pH was adjusted to 3.3 with citric acid. After sterilization using plate sterilization, the bottle is filled and then pasteurized to produce a beverage.
オルニチン、シトルリンおよびアルギニンを含有する飲料の製造(2)
実施例1で作成したアミノ酸組成物20 mg、適当量の果糖ぶどう糖液糖、食塩、クエン酸、香料、クエン酸ナトリウム、乳酸カルシウム、ピロリン酸鉄、グルコン酸カルシウム、塩化カリウム、塩化マグネシウム、甘味料とを配合し555 mLの飲料を製造する。Manufacture of beverages containing ornithine, citrulline and arginine (2)
20 mg of amino acid composition prepared in Example 1, appropriate amount of fructose glucose liquid sugar, salt, citric acid, flavor, sodium citrate, calcium lactate, iron pyrophosphate, calcium gluconate, potassium chloride, magnesium chloride, sweetener To make a 555 mL beverage.
オルニチン、シトルリンおよびアルギニンを含有する飲料の製造(3)
実施例1で作成したアミノ酸組成物3000 mg、適当量のしょ糖、トレハロース、酸味料、香料、重曹、増粘剤(ペクチン)、甘味料(ステビア)を配合し190 mLの飲料を製造する。Manufacture of beverages containing ornithine, citrulline and arginine (3)
A 190 mL beverage is prepared by blending 3000 mg of the amino acid composition prepared in Example 1, an appropriate amount of sucrose, trehalose, acidulant, flavor, baking soda, thickener (pectin), and sweetener (stevia).
オルニチン、シトルリンおよびアルギニンを含有するゼリータイプ飲料の製造
実施例1で作成したアミノ酸組成物1800 mg、適当量のエリスリトール、しょ糖、ゲル化剤(増粘多糖類(リンゴ由来を含む)、クエン酸、香料、乳酸カルシウム、クエン酸ナトリウム、甘味料(スクラロース、ステビア)を配合し180 gのゼリータイプ飲料を製造する。Production of jelly type beverage containing ornithine, citrulline and arginine 1800 mg of the amino acid composition prepared in Example 1, erythritol, sucrose in an appropriate amount, gelling agent (thickening polysaccharide (including apple origin), citric acid, A 180 g jelly type beverage is produced by blending flavoring, calcium lactate, sodium citrate and sweeteners (sucralose, stevia).
本発明により、特定のアミノ酸と蛋白質を有効成分とする、安全な筋肉増強剤または組成物が提供される。 According to the present invention, a safe muscle enhancer or composition comprising specific amino acids and proteins as active ingredients is provided.
Claims (8)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014047569 | 2014-03-11 | ||
| JP2014047569 | 2014-03-11 | ||
| PCT/JP2015/057130 WO2015137387A1 (en) | 2014-03-11 | 2015-03-11 | Muscle enhancing drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2015137387A1 true JPWO2015137387A1 (en) | 2017-04-06 |
Family
ID=54071829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507786A Pending JPWO2015137387A1 (en) | 2014-03-11 | 2015-03-11 | Muscle enhancer |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2015137387A1 (en) |
| WO (1) | WO2015137387A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3402476A4 (en) * | 2016-01-13 | 2019-09-18 | Metabolic Technologies, Inc. | Compositions and methods of use of -hydroxy- -methylbutyrate (hmb) for joint stability |
| JP2018090504A (en) * | 2016-11-30 | 2018-06-14 | 株式会社東洋新薬 | Muscle enhancing composition |
| CN110402088A (en) * | 2017-03-28 | 2019-11-01 | 味之素株式会社 | For improving the food of intestinal environment |
| JP2019024389A (en) * | 2017-07-28 | 2019-02-21 | 株式会社明治 | Amino acid composition for improved muscle strength |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006514550A (en) * | 2002-12-20 | 2006-05-11 | ジエル・ダイナミツクス・エル・エル・シー | Nutritional supplement compositions and methods |
| JP2010506887A (en) * | 2006-10-17 | 2010-03-04 | ユニヴェルシテ パリ デカルト | Use of citrulline for the treatment of undernourishment |
| JP2012012327A (en) * | 2010-06-30 | 2012-01-19 | Morinaga & Co Ltd | Food for myopachynsis promotion, auxiliary food, and supplement |
| WO2012143403A1 (en) * | 2011-04-18 | 2012-10-26 | Nestec S.A. | Nutritional compositions having alpha-hica and citrulline |
| JP2012256513A (en) * | 2011-06-09 | 2012-12-27 | Shuji Iwata | Organic el element and light-emitting device |
| JP2013509395A (en) * | 2009-10-28 | 2013-03-14 | モデュテック エス．エー． | Preparations containing amino acids and plants and their activity in alcohol detoxification |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4397663B2 (en) * | 2003-02-04 | 2010-01-13 | 江崎グリコ株式会社 | Muscle mass increasing agent |
-
2015
- 2015-03-11 JP JP2016507786A patent/JPWO2015137387A1/en active Pending
- 2015-03-11 WO PCT/JP2015/057130 patent/WO2015137387A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006514550A (en) * | 2002-12-20 | 2006-05-11 | ジエル・ダイナミツクス・エル・エル・シー | Nutritional supplement compositions and methods |
| JP2010506887A (en) * | 2006-10-17 | 2010-03-04 | ユニヴェルシテ パリ デカルト | Use of citrulline for the treatment of undernourishment |
| JP2013509395A (en) * | 2009-10-28 | 2013-03-14 | モデュテック エス．エー． | Preparations containing amino acids and plants and their activity in alcohol detoxification |
| JP2012012327A (en) * | 2010-06-30 | 2012-01-19 | Morinaga & Co Ltd | Food for myopachynsis promotion, auxiliary food, and supplement |
| WO2012143403A1 (en) * | 2011-04-18 | 2012-10-26 | Nestec S.A. | Nutritional compositions having alpha-hica and citrulline |
| JP2012256513A (en) * | 2011-06-09 | 2012-12-27 | Shuji Iwata | Organic el element and light-emitting device |
Non-Patent Citations (3)
| Title |
|---|
| OSOWSKA S, AMERICAN JOURNAL OF PHYSIOLOGY : ENDOCRINOLOGY AND METABOLISM, 2006, V291 N3, P.E582-E586, JPN7018003347, ISSN: 0004004844 * |
| トレピ通信 ＳＭＤ プロ ホエイプロテイン 超回復をするために,［ONLINE］, 2010.04.13, インターネット, JPN7018003345, ISSN: 0004004842 * |
| 森下 幸治, アミノ酸と筋タンパク分解抑制, 臨床スポーツ医学, 2005.07.01, ＶＯＬ．２２，ＮＯ．７, ７９, JPN7018003346, ISSN: 0004004843 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015137387A1 (en) | 2015-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7932288B2 (en) | Composition for relieving subjective symptoms of fatigue | |
| EP1913943B1 (en) | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria | |
| JP5188181B2 (en) | Composition for suppressing increase in blood alcohol concentration | |
| WO2015137387A1 (en) | Muscle enhancing drug | |
| JP5053535B2 (en) | Oral for improving sleep or waking up | |
| JPWO2007077995A1 (en) | Muscle bulking agent | |
| JP6807083B2 (en) | Muscle-building compositions and methods for building muscle | |
| JP5712393B2 (en) | Collagen absorption promoter and use thereof | |
| JP5885784B2 (en) | Oral composition | |
| JP2008044890A (en) | Composition for breast enlargement and food and beverage for breast enlargement | |
| JP6848962B2 (en) | Behavioral fitness improver | |
| JP2009254242A (en) | Novel sweetener having sugar-like taste, method for producing the same, and use of the sweetener | |
| JP4847732B2 (en) | Cold remedy | |
| JP2013124222A (en) | Visceral fat reducing agent | |
| KR20240145579A (en) | Composition for improving muscular function comprising fermented whey protein as effective component | |
| JP6052566B2 (en) | Fatigue odor inhibitor | |
| WO2022075297A1 (en) | Food and drink, anti-fatigue agent, and endurance improver | |
| JP5943516B2 (en) | Sweetener for improving biological function comprising D-sorbose as an active ingredient | |
| JP2012077010A (en) | Composition for building muscle | |
| JP2020094021A (en) | Novel method for producing resveratrol derivative and novel use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180123 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181002 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190402 |